The Muscle-First Pill Aiming to Burn Fat While Sparing Strength
Key Takeaways:
- A new oral drug boosts muscle metabolism instead of suppressing appetite. In early studies, this β2-agonist–based pill nudged skeletal muscle to burn more fuel, improving blood sugar regulation and body composition without reducing hunger.
- It appears to favor fat loss while sparing muscle. In animals, the treatment increased fat burning and improved markers of glucose handling while preserving lean mass, a key priority for healthy weight management and aging.
- Early human data look encouraging but preliminary. A phase I trial in volunteers found the tablet was generally well tolerated and suitable for once-daily dosing, with larger phase II studies now being planned.
Much of the conversation around modern weight-management drugs centers on the brain: injectable GLP-1–based medications like semaglutide work primarily by dialing down appetite and changing how we respond to food cues. The new experimental tablet from Karolinska Institutet and Stockholm University flips that script, targeting skeletal muscle directly. Instead of telling you to eat less, it appears to tell your muscles to burn more.
Muscle as a Metabolic Engine
The compound is a lab-designed β2 agonist built to activate key signaling pathways in skeletal muscle while avoiding the heart overstimulation that has limited older drugs in this class. In animal studies, this translated into better blood sugar control and more favorable body composition: higher fat oxidation, lower fat mass, and preserved lean tissue. Because muscle is a major sink for glucose and a driver of resting energy expenditure, gently increasing its metabolic activity can have outsized effects on whole-body fuel use.
Unlike appetite-suppressing drugs, this approach did not blunt hunger or trigger the same digestive side effects in early work. That makes it conceptually closer to an “exercise-mimicking” strategy—supporting the tissues that burn energy—than to a satiety tool.
Where the Research Stands Now
So far, the pill has moved through a phase I trial in 48 healthy volunteers and 25 people with disrupted glucose regulation, where it showed a tolerable safety profile and pharmacokinetics consistent with once-daily oral dosing. Researchers emphasize that efficacy data in larger, more diverse groups are still missing, and the drug is not yet available outside clinical studies.
For the longevity field, this candidate illustrates a broader shift: away from purely brain-centric weight strategies and toward preserving and energizing skeletal muscle as a central organ of metabolic health. If future trials confirm that muscle-targeted drugs can improve glucose handling and body composition while maintaining appetite and lean mass, they could complement existing therapies or offer an alternative route for those prioritizing strength and physical function over maximum scale loss.
References:
- Aikaterini Motso, Benjamin Pelcman, Anastasia Kalinovich, Nour Aldin Kahlous, Muhammad Hamza Bokhari, Nodi Dehvari, Carina Halleskog, Erik Waara, Jasper de Jong, Elizabeth Cheesman, Christine Kallenberg, Gopala Krishna Yakala, Praerona Murad, Erika Wetterdal, Pia Andersson, Sten van Beek, Anna Sandström, Diane Natacha Alleluia, Emanuela Talamonti, Sonia Youhanna, Pierre Sabatier, Claire Koenig, Sabine Willems, Aurino M. Kemas, Dana S. Hutchinson, Seungmin Ham, Lukas Grätz, Jan Voss, Jose G. Marchan-Alvarez, Martins Priede, Krista Jaunsleine, Jana Spura, Vadims Kovada, Linda Supe, Leigh A. Stoddart, Nicholas D. Holliday, Phillip T. Newton, Nicolas J. Pillon, Gunnar Schulte, Roger J. Summers, Ilga Mutule, Edgars Suna, Jesper V. Olsen, Peter Molenaar, Jens Carlsson, Volker M. Lauschke, Shane C. Wright, Tore Bengtsson. GRK-biased adrenergic agonists. Cell, 2025; 188 (19): 5142 DOI: 10.1016/j.cell.2025.05.042